Navigation Links
UCB Launches Research Alliance with Harvard University
Date:6/30/2011

BOSTON and BRUSSELS, June 30, 2011 /PRNewswire/ -- UCB and Harvard University officially launched their innovative Research Alliance during a signing ceremony that took place in Boston last night in the presence of his Royal Highness Prince Philippe of Belgium.

(Photo: http://photos.prnewswire.com/prnh/20110630/NY28450 )

The Alliance creates a unique drug discovery bridge between industry and academia, with Harvard scientists continuing their research that holds potential for the development of new therapeutic modalities in clinical medicine. The strategy underlying the collaborative alliance is to advance ongoing Harvard research projects along the drug development pathway.

"Harvard's world-class academic research is an excellent fit with UCB's world-class antibody research and central nervous system (CNS) pharmacology," said Ismail Kola, President of UCB NewMedicines. "Both parties will learn from each other through the collaboration and a two-way exchange of ideas. Harvard will benefit from UCB's strengths and industry experience in drug discovery and development; while Harvard's exceptional research will complement UCB's internal expertise.''

The first research project funded under the Harvard-UCB alliance is a collaboration with Professor Gokhan S. Hotamisligil, M.D., Ph.D., Chair, Department of Genetics and Complex Diseases, Harvard School of Public Health, to generate and develop antibodies against an exciting target with potential application in a range of diseases including diabetes and metabolic disorders.

"We couldn't be more pleased about entering into this innovative collaboration with UCB, which joins together leaders in academia and industry to advance pioneering research from the lab to the clinic," said Isaac T. Kohlberg, Harvard's Chief Technology Development Officer and head of its Office of Technology Development. "In furtherance of our mis
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
2. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
3. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
4. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
5. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
6. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
7. Premier Micronutrient Launches Supplement for Hearing Health
8. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
9. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
10. Seal Shield Launches Worlds First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control
11. PositiveFriends.com Launches STD Social Networking Site Balancing Dating with Online Support Features
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 2, 2015 Releases of the ... Aedes aegypti , , reduced the dengue mosquito ... by 95%, well below the modelled threshold ... , The journal PLOS Neglected Tropical Diseases ... genetically engineered mosquitoes. The results showed that in Juazeiro ...
(Date:7/2/2015)... July 2, 2015   EVO Aesthetic Center and ... provider for non-invasive aesthetics in Lakeway, Texas ... treatments with the Astanza Duality laser. The medical spa ... through various medical and laser procedures. Their addition of ... a clear solution to their tattoo regret. ...
(Date:7/2/2015)... DURHAM, N.C. , July 2, 2015 ... of assets related to the ion channel biology platform ... previously been obtained as part of Pfizer,s 2011 acquisition ... Pfizer,s rights to the "Icagen" name and trademark.  XRPro ... comprehensive services for ion channel and transporter drug discovery, ...
Breaking Medicine Technology:Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 3EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4
... Echo Therapeutics,(OTC Bulletin Board: ECTE) today announced ... Symphony(TM) Transdermal Continuous Glucose Monitoring (tCGM),System in ... Diabetes. Echo,s non-invasive,Symphony tCGM System consists of ... the Prelude(TM) SkinPrep System, which,incorporates leading-edge, needle-free ...
... MITI ), a biopharmaceutical company developing novel, ... autoimmune,diseases, today announced that it will host a ... 2008, at 9:00 am Eastern Time (3:00 pm,Central ... financial,results. Micromet anticipates releasing its financial results at ...
Cached Medicine Technology:Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 2Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 3Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 4Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 2Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 3
(Date:7/2/2015)... ... 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce the opening of its newest ... Lone Star State. The premium frozen yogurt chain was listed as #22 on the Inc. ... in the Village at Bachman Lake, is located at:, 3701 W. Northwest Highway, STE 430, ...
(Date:7/2/2015)... ... ... the recent report by JAMA Internal Medicine published on June 22, 2015, ... declared a war on obesity in the United States. , "Obesity is one of ... magnitude of this discovery. For that reason, I am declaring, along with my Health ...
(Date:7/2/2015)... ... 02, 2015 , ... When Walker Parking Consultants specified Kenall ... Minnesota, they knew it would save the university energy and maintenance costs. What ... total energy savings after installation was an impressive 89 percent, which resulted in ...
(Date:7/2/2015)... ... ... full swing, Americans are flocking to Canada’s many lakes to reel in their fair share ... and it’s easy to understand why. From the Pacific Northwest Coast of British Columbia to ... a huge industry, and Americans make up the vast majority of anglers from outside of ...
(Date:7/2/2015)... ... ... LIFX ” was featured on NewsWatch as part of its monthly Tech Report, which ... expert and special reporter for NewsWatch, conducted the review and shared with viewers how ... According to the U.S. Department of Energy, it’s very important to use energy-efficient light ...
Breaking Medicine News(10 mins):Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2
... increased over the past years with more than one-third ... alternative medicine. Alternative or complementary therapies include treatments such ... vitamins. ,Researchers in Boston compared the results ... National Health Interview Survey taken in 2002. Results showed ...
... disorder, where white blood cells attack fatty tissue surrounding nerve ... is twice as common in women as in men . ... with multiple sclerosis. Since MS causes muscle weakness and fatigue, ... of life, researchers designed an exercise program to develop ...
... in as little as two days of physical inactivity, the ... and other related diseases.// ,Researchers conducted a study in ... stayed inactive. When the rats stopped running for two days ... of sugar taken into the muscle in response to insulin ...
... children who have Duchenne muscular dystrophy (DMD) with the oral ... despite the side effects of the drug . Most patients ... teens or early 20s from respiratory failure or heart problems. ... questioned whether its side effects, which can range from weight ...
... carry a gene that produces a higher level of ... for stroke.// ,Researchers reviewed medical literature on homocysteine ... study results were observational in nature. A standard scientific ... looking at data on the link between homocysteine and ...
... disease who follow a heart-healthy diet and weight-loss regimen ... that raise HDL (high-density lipoproteins or "good" cholesterol) levels, ... patients younger than 76 with low HDL and known ... a heart-healthy diet and lost weight. However, results showed ...
Cached Medicine News:
... Measles IgG Enzymelinked Immunosorbent Assays(ELISA) is intended ... IgG antibody to Measles Rubeola) virus in ... used for the determination of immune status. ... to demonstrate seroconversion or a significant rise ...
The DSL-05-01-MEM Measles IgM Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgM-class antibodies to Measles virus in human serum. This assay is intended fo...
The DSL-05-10-MEG Measles IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgG-class antibodies to Measles Virus in human serum. This assay is intended fo...
... is a glucocorticoid produced by the adrenal ... It is secreted with a circadian periodicity, ... the morning. Cortisol is often elevated in ... stress, AIDS, and in the visceral fat ...
Medicine Products: